Stock Screener App

Gratuito -

2.02

0.98% -0.02

Oragenics Inc (OGEN)

Panoramica Notizia Cronologia dei prezzi Forum Previsione Frazionamento azionario

Oragenics Inc Borsa (OGEN) Ultime notizie

Closing Bell Recap: Oragenics Inc (OGEN) Ends at 2.04, Reflecting a 3.55 Upturn – DWinneX - The Dwinnex

Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com - Defense World

Ratio Examination: Oragenics Inc (OGEN)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com Canada

Investing.com Canada

Oragenics Appoints William “Frank” Peacock MD As Chief Clinical Officer - citybiz

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com Australia

Investing.com Australia

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com UK

Investing.com UK

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - GlobeNewswire

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - Yahoo Finance

Holdings of Oragenics Inc (OGEN) are aligned with the stars – Sete News - SETE News

ImmunityBio (NASDAQ: IBRX) Advances in Oncology: Gearing Up for ANKTIVA's Commercial Rollout - BP Journal

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

Oragenics prepares ONP-002 for Phase II concussion trial - TipRanks.com - TipRanks

Oragenics, Inc (NYSE: OGEN) Surges 34% Amidst Webinar Announcement and Intranasal Pharmaceutical Development - BP Journal

Nuburu Inc (NYSE: BURU) Surges Amid Exciting Developments - BP Journal

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - GlobeNewswire

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - Markets Insider

Markets Insider

Oragenics climbs 9% amid Phase 2 study, business updates - MSN

Oragenics climbs 9% amid Phase 2 study, business updates (NYSE:OGEN) - Seeking Alpha

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - GlobeNewswire

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - Markets Insider

Markets Insider

Oragenics climbs 9% amid Phase 2 study, business updates (NYSE:OGEN) - Seeking Alpha

Oragenics: Q1 Earnings Snapshot | Business | valdostadailytimes.com - Valdosta Daily Times

Valdosta Daily Times

Oragenics: Q1 Earnings Snapshot - Milford Mirror

Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference - The Globe and Mail

The Globe and Mail

Oragenics, Inc. Announces New Chair - The Globe and Mail

The Globe and Mail

SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice - The Globe and Mail

The Globe and Mail

Oragenics, Inc. Announces $6.5 Million Registered Direct Offering - The Globe and Mail

The Globe and Mail

Oragenics to Participate in the World Vaccine Congress Washington - The Globe and Mail

The Globe and Mail

Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine - The Globe and Mail

The Globe and Mail

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - Markets Insider

Markets Insider

Oragenics Inc Reports SEC Filing Update - TipRanks.com - TipRanks

Oragenics partners with Avance Clinical for Phase 2 concussion study (NYSE:OGEN) - Seeking Alpha

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - GlobeNewswire

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - GlobeNewswire

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

Sarasota biotech company noncompliant with NYSE listing standards - Business Observer

Business Observer

Oragenics advances with new neurological treatment platform - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

Oragenics Announces Closing of Public Offering - Business Wire

S&P 500 Edges Lower; ADT Posts Upbeat Earnings

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels

Dow Dips 200 Points; TJX Posts Upbeat Sales

Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket

Oragenics Inc Announces Proposed Public Stock Offering - TipRanks.com - TipRanks

Oragenics Shares Tumble Premarket After Stock Offering - MarketWatch

$75.07

0.79%

$148.85

3.50%

$28.20

0.75%

$148.43

1.07%

$371.02

2.45%

$100.60

1.87%

Apri su Yahoo | Apri su Google | Aperto in Finviz